Search Results - "Method, Michael"

A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2- early breast cancer in the United States.

Authors: Brown, Jacqueline Scardo, Savannah Method, Michael et al.

Source: BMC Cancer. Dec2022, Vol. 22 Issue 1, p1-20. 20p.

Exposure–response relationships of mirvetuximab soravtansine in patients with folate receptor‐α‐positive ovarian cancer: Justification of therapeutic dose regimen.

Authors: Tu, Ya‐Ping Lagraauw, H. Maxime Method, Michael et al.

Source: British Journal of Clinical Pharmacology. Jan2025, Vol. 91 Issue 1, p220-231. 12p.

Management of Endometrial Precancers.

Authors: Trimble, Cornelia L. Method, Michael Leitao, Mario et al.

Source: Obstetrics & Gynecology. Nov2012, Vol. 120 Issue 5, p1160-1175. 16p.

Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer.

Authors: Matulonis, Ursula A. Vergote, Ignace Moore, Kathleen N. et al.

Source: Gynecologic Oncology. Sep2025, Vol. 200, p96-104. 9p.

Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics.

Authors: Nelson, David R. Brown, Jacqueline Morikawa, Aki et al.

Source: PLoS ONE. 2/25/2022, Vol. 17 Issue 2, p1-21. 21p.

Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha–expressing recurrent ovarian cancer: An integrated safety summary.

Authors: Moore, Kathleen N. Lorusso, Domenica Oaknin, Ana et al.

Source: Gynecologic Oncology. Dec2024, Vol. 191, p249-258. 10p.

Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer.

Authors: Richardson, Debra L. Moore, Kathleen N. Vergote, Ignace et al.

Source: Gynecologic Oncology. Jun2024, Vol. 185, p186-193. 8p.

Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor‐α positive ovarian cancer: The antibody–drug conjugate, payload and metabolite.

Authors: Tu, Ya‐Ping Hanze, Eva Zhu, Fengying et al.

Source: British Journal of Clinical Pharmacology. Feb2024, Vol. 90 Issue 2, p568-581. 14p.

Identification of the optimal pathway to reach an accurate diagnosis in the absence of an early detection strategy for ovarian cancer

Authors: Hess, Lisa M. Stehman, Frederick B. Method, Michael W. et al.

Source: Gynecologic Oncology. Dec2012, Vol. 127 Issue 3, p564-568. 5p.

Patient–provider communication and perceived control for women experiencing multiple symptoms associated with ovarian cancer

Authors: Donovan, Heidi Scharf Hartenbach, Ellen M. Method, Michael W.

Source: Gynecologic Oncology. Nov2005, Vol. 99 Issue 2, p404-411. 8p.

Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study

Authors: Muggia, Franco M. Blessing, John A. Method, Michael et al.

Source: Gynecologic Oncology. Feb2004, Vol. 92 Issue 2, p639. 5p.

Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.

Authors: Gilbert, Lucy Oaknin, Ana Matulonis, Ursula A. et al.

Source: Gynecologic Oncology. Mar2023, Vol. 170, p241-247. 7p.

Patient-reported outcome results from phase III MIRASOL trial of mirvetuximab soravtansine versus investigator's choice of chemotherapy in FRα-positive, platinum-resistant ovarian cancer.

Authors: Konecny, Gottfried Moore, Kathleen Lebreton, Coriolan et al.

Source: Gynecologic Oncology. 2024 Supplement 1, Vol. 190, pS11-S12. 2p.

Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study.

Authors: Brewer, Molly Angioli, Roberto Scambia, Giovani et al.

Source: Gynecologic Oncology. Mar2020, Vol. 156 Issue 3, p523-529. 7p.

Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma.

Authors: Rose, Peter G. MD Java, James J. PhD Salani, Ritu MD et al.

Source: Obstetrics & Gynecology. Feb2019, Vol. 133 Issue 2, p245-254. 10p.

A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study.

Authors: Rossi, Emma C Kowalski, Lynn D Scalici, Jennifer et al.

Source: Lancet Oncology. Mar2017, Vol. 18 Issue 3, p384-392. 9p.

Cognitive function during and six months following chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: An NRG oncology/gynecologic oncology group study.

Authors: Hess, Lisa M. Huang, Helen Q. Hanlon, Alexandra L. et al.

Source: Gynecologic Oncology. Dec2015, Vol. 139 Issue 3, p541-545. 5p.

PICCOLO: An open-label, single arm, phase 2 study of mirvetuximab soravtansine in recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate-alpha (FRα) expression (300).

Authors: Secord, Angeles Alvarez Lewin, Sharyn Murphy, Conleth et al.

Source: Gynecologic Oncology. 2022 Supplement 1, Vol. 166, pS157-S158. 2p.

MIRASOL: A randomized, open-label, phase 3 study of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate-alpha (FRα) expression (297)

Authors: Moore, Kathleen Konecny, Gottfried Martin, Lainie et al.

Source: Gynecologic Oncology. 2022 Supplement 1, Vol. 166, pS156-S157. 2p.

Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).

Authors: Penson, Richard T Huang, Helen Q Wenzel, Lari B et al.

Source: Lancet Oncology. Mar2015, Vol. 16 Issue 3, p301-311. 11p.